Stock analysts at StockNews.com initiated coverage on shares of Genetic Technologies (NASDAQ:GENE – Get Rating) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.
Genetic Technologies Stock Up 0.9 %
Shares of Genetic Technologies stock opened at $1.09 on Wednesday. Genetic Technologies has a one year low of $0.83 and a one year high of $2.40. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.08 and a quick ratio of 1.98. The business has a 50-day simple moving average of $1.19 and a 200-day simple moving average of $1.19.
Hedge Funds Weigh In On Genetic Technologies
A number of institutional investors and hedge funds have recently made changes to their positions in GENE. OLD Mission Capital LLC acquired a new position in shares of Genetic Technologies during the third quarter worth about $39,000. Continental Investors Services Inc. purchased a new stake in Genetic Technologies during the third quarter worth approximately $47,000. Finally, Susquehanna International Group LLP lifted its stake in Genetic Technologies by 148.2% during the fourth quarter. Susquehanna International Group LLP now owns 76,881 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 45,901 shares during the last quarter. 1.22% of the stock is owned by institutional investors and hedge funds.
Genetic Technologies Company Profile
Genetic Technologies Ltd. is a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. It operates through EasyDNA and GeneType/Corporate segments. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The GeneType/Corporate segment includes tha GeneType branded test sales and expenses, including corporate charges.
- Get a free copy of the StockNews.com research report on Genetic Technologies (GENE)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.